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Abstract
Background: ALK-rearranged lung cancers exhibit specific pathologic and clinical features and are responsive to
anti-ALK therapies. Therefore, the detection of ALK-rearrangement is fundamental for personalized lung cancer
therapy. Recently, new molecular techniques, such as NanoString nCounter, have been developed to detect ALK
fusions with more accuracy and sensitivity.
Methods: In the present study, we intended to validate a NanoString nCounter ALK-fusion panel in routine biopsies of
FFPE lung cancer patients. A total of 43 samples were analyzed, 13 ALK-positive and 30 ALK-negative, as previously
detected by FISH and/or immunohistochemistry.
Results: The NanoString panel detected the presence of the EML4-ALK, KIF5B-ALK and TFG-ALK fusion variants. We observed
that all the 13 ALK-positive cases exhibited genetic aberrations by the NanoString methodology. Namely, six cases (46.15%)
presented EML-ALK variant 1, two (15.38%) presented EML-ALK variant 2, two (15.38%) presented EML-ALK variant 3a, and
three (23.07%) exhibited no variant but presented unbalanced expression between 5’/3’ exons, similar to other positive
samples. Importantly, for all these analyses, the initial input of RNA was 100 ng, and some cases displayed poor RNA quality
measurements.
Conclusions: In this study, we reported the great utility of NanoString technology in the assessment of ALK fusions in
routine lung biopsies of FFPE specimens.
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Background
The anaplastic lymphoma kinase (ALK) gene is located
in the 2p23 chromosome region and codifies a tyrosine
kinase receptor of the insulin receptor family [1].
Genetic aberrations in the ALK gene were first described in
anaplastic large cell lymphoma by Morris and colleagues
[1] as part of an oncogenic fusion protein resulting from
the translocation between chromosomes 2 and 5 (t[2;5]
[p23;q35]) (NPM-ALK - Nucleophosmin- anaplastic lymph-
oma kinase). In 2007, Soda and colleagues concluded that
the ALK gene fusion was also an oncogenic driver of non--
small cell lung cancer (NSCLCs) [2]. In these tumors, the
most common fusion partner, the EML4 (Echinoderm
microtubule-associated protein-like 4) gene, results from a
small inversion within the short arm of chromosome 2, and
it is found in approximately 3–7% of NSCLCs [2, 3]. Other
partners encoding KIF5B-ALK (<1%), TFG-ALK (2%),
KLC1-ALK (<5%), PTPN3-ALK (<1%) and in rare events
and isolated cases the aberrant proteins HIP1-ALK, TPR-
ALK, STRN-ALK, and A2M-ALK have also been described
in cancers [4–6]. The aberrant ALK fusions promote
dimerization domains that are ligand independent, with
consequent constitutive kinase activity and malignant
transformation [5].
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ALK-rearranged lung cancers exhibit specific clinical
and pathologic features [7]. They are associated with
younger patients (<50 years), non-smokers, prevalent
mucinous histology, signet ring morphology in some
cases, and EGFR and KRAS wild-type cases [3, 8, 9]. Im-
portantly, ALK rearrangement predicts the clinical re-
sponse to Crizotinib (Xalkori®, Pfizer), an oral MET/ALK
inhibitor, ATP-competitive inhibitors of the ALK
tyrosine kinase, Ceritinib (Zykadia™, Novartis) and
Alectinib (Alecensa®, Roche), second-generation ALK in-
hibitors, and lorlatinib (PF-06463922) [10, 11].
Consequently, accurate molecular methodologies that
detect and quantify ALK fusions and their variants have
been developed for therapeutic selection. Recently, an
ALK fusion panel was designed and tested using Nano-
String technology, which is considered a more sensitive
method since it performs direct molecule counting,
avoiding the bias associated with amplification [12–14].
The ALK panel was created using two strategies. The
first group of eight probes over several exons was de-
signed to detect an unbalanced expression. The second
set of probes was designed in the breakpoint of the
known variants of EML4-ALK, KIF5B-ALK and TFG-
ALK. For this strategy, a pair of adjacent probes (35–
50 bp each) were used, the first (biotin-capture probe)
complementary to the partner gene, and the other (bar-
coded reporter probe) to the ALK gene at exon 20 [13].
In the present study, we reported the feasibility of the
NanoString ALK fusion panel to detect the ALK fusion
transcripts in formalin-fixed paraffin-embedded (FFPE)
samples of lung adenocarcinoma in a Brazilian popula-
tion. We also evaluated whether a lower quantity (up to
100 ng) of RNA could be used in a routine diagnostic
setting of tumor biopsies.
Methods
Material
In the present study, we performed a retrospective
evaluation of a convenience series of 43 lung carcinoma
samples from the Pathology Department of Barretos
Cancer Hospital (Brazil) between 2012 and 2015
(Additional file 1: Table S1). These cases were selected
based on their previous evaluation for ALK rearrangement
by immunohistochemistry and/or fluorescence in situ
hybridization (FISH) in our Department of Pathology.
The cases were also assessed for EGFR and KRAS
mutation status.
As controls, we used the lung adenocarcinoma cell
lines H2228 (ALK-positive) and CALU3 (ALK-negative)
(ATCC, Manassas, VA). Cell monolayers were grown in
Dulbecco’s modified Eagle’s medium (DMEM) (Gibco)
supplemented with 10% fetal bovine serum (Gibco) and
1% penicillin-streptomycin (Gibco). The cells were incu-
bated in a 5% CO2 environment at 37 °C.
This study was approved by the Barretos Cancer
Hospital Ethical Review Committee ((#630/2012). Due
the retrospective nature of the study, the Local Ethical
Review Committee waived the need for patients written
informed consent.
DNA isolation
Serial 5-μm unstained sections of formalin-fixed paraffin-
embedded blocks were cut, and one adjacent hematoxylin
and eosin-stained (H&E) section was taken for pathologist
identification and selection of the tumor tissue. DNA was
macrodissected from 1 unstained section from each speci-
men as previously described [15, 16]. Briefly, tissues were
deparaffinized at 80 °C and serially washed with xylene
and ethanol (100, 70 and 50%). Selected areas of the
tumor or precursor lesions were macrodissected using a
sterile needle (18G × 1 1/2) (BD, Curitiba, Brazil) and care-
fully collected into a microtube. DNA was extracted using
a QIAamp DNA Micro Kit (Qiagen, Hilden, Germany)
following the manufacturer’s instructions. DNA quantity
and quality was evaluated by Nanodrop 2000 (Thermo
Scientific, Wilmington, USA). DNA samples were diluted
to a final concentration of 50 ng/μl and stored at −20 °C
for further molecular analysis.
Mutational analysis of EGFR and KRAS
The hotspot regions of the oncogenes EGFR (exons 18, 19,
20 and 21) and KRAS (codons 12/13) were analyzed by
polymerase chain reaction (PCR), followed by direct se-
quencing, as previously described [17]. Briefly, PCR was
performed in a final volume of 15 μl, with 50 ng of DNA
and 10 μM of forward and reverse primers, using 7.5 μl of
the HotStar master mix (Qiagen, Hilden, Germany) accord-
ing to the protocol proposed by the manufacturer, with the
following cycling parameters: 96 °C for 15 min, followed by
40 cycles of 96 °C for 45 s, 58 °C for 45 s (EGFR) or 56.5 °C
for 45 s (KRAS), 72 °C for 45 s and 72 °C for 10 min in a
thermocycler (Veriti, Applied Biosystems, Carlsbad, USA).
Primer sequences were previously described [15]. The PCR
products were evaluated by electrophoresis in agarose gel
and further purified using ExoSAP-it (Affymetrix), followed
by cycle sequencing carried out using a BigDye Terminator
v3.1 Cycle Sequencing kit (Applied Biosystems, Foster City,
CA) with an initial denaturation at 97 °C for 3 min,
followed by 28 cycles of 96 °C for 10 s, 50 °C for 5 s, and
60 °C for 4 min. Sequencing products were purified using
BigDye Xterminator (Applied Biosystems) and analyzed on
a 3500 DNA Analyzer with a ABI capillary electrophoresis
system (Applied Biosystems). Sequences were analyzed
using the SeqScape software package (Applied Biosystems).
Fluorescence in situ hybridization (FISH) Assay
The presence of ALK gene rearrangement was deter-
mined using fluorescence in situ hybridization (FISH)
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assay using the commercially available ALK probe (Vysis
LSI ALK Dual Color, Break Apart Rearrangement Probe;
Abbott Molecular, Abbott Park, IL) as described else-
where [18]. The lung adenocarcinoma cell lines H2228
(ALK-positive) and CALU3 (ALK-negative) were used as
the positive and negative control, respectively. Paraffin-
embedded sections (5 μm thick) were initially incubated
at 60 °C, deparaffinized with xylene and dehydrated in
100% ethanol. Tissue sections were then transferred to a
0.2 N HCL solution and incubated at 80 °C with 10 mM
citrate at pH 6.4 and 1 mM EDTA at pH 8.0. Slides were
enzymatically treated with pepsin in 0.01 N HCL and
washed once with water. Five microliters of the ALK
probe was applied to the tumor tissue, and a subsequent
denaturation step was performed at 83 °C for 10 min.
Hybridization was carried out for 22 h in a humidified
chamber at 37 °C. Tissue sections were washed in 0.3%
Igepal/2x SSC at 63 °C for 4 min, and then washed with
2x SSC at room temperature. Nuclei were counter-
stained with DAPI (4’,6-diamidino-2-phenylindole) and
analyzed using an Eclipse 50i microscope with fluores-
cence (Nikon Instruments). From each sample, 100
tumor nuclei per slide were analyzed, and the standard
score of > = 15% was used to determine the presence of
ALK rearrangement, as previously reported [18, 19]. For
the analysis, the software FISHView 6.0 (Applied
Spectral Imaging) was used.
Immunohistochemistry (IHC)
The presence of ALK overexpression was assessed by im-
munohistochemistry (IHC) staining using 4-μm-thick sec-
tions. Ganglion cells present in sections of the appendix
were used as positive controls, and in negative controls,
the primary antibody was omitted. Immunohistochemical
reactions were performed at Ventana Benchmark XT
using the Ventana ALK (D5F3) CDx assay (Ventana,
Tucson, AZ, clone 790–4796) according to the manufac-
turer. In brief, slides of the NSCLC tumor were subjected
to deparaffinization using EZ Prep (Ventana, Tucson, AZ)
and antigen retrieval was performed using Cell Condition-
ing 1 (Ventana, Tucson, AZ). Tissue sections were then
incubated with anti-ALK antibody (clone D5F3, Ventana,
Tucson, AZ) for 20 min. The OptiView DAB IHC Detec-
tion Kit (Ventana, Tucson, AZ) and OptiView Amplifica-
tion Kit (Ventana, Tucson, AZ) were used according to
the manufacturer’s recommendations for the visualization
of the bound primary antibody. The ALK stain was con-
sidered positive if at least one cell presented strong dark
brown cytoplasmic staining as stated in the kit’s manual as
previously described [20].
RNA isolation
Tumor cell content (>60%) was assessed based on H&E-
stained slides, and RNA was isolated from two to four
sections (10 μm thick) using a RecoverALL total Nucleic
Acid Isolation kit (Life Technologies) according to the
manufacturer’s instructions. Briefly, the process is di-
vided into four steps: (i) an initial preparation that in-
cludes slide scraping, deparaffinization with xylene and
100% ethanol dehydration; (ii) protease digestion; (iii)
nucleic acid isolation using the filter cartridge, followed
by washing; and (iv) DNase digestion with additional
washes and elution. RNA concentration was assessed
using both the Nanodrop 1000 spectrophotometer
(NanoDrop Products, Thermo Scientific, Wilmington,
DE) and Qubit (Life Technologies).
NanoString nCounter Assay
The custom ALK panel was carried out using the Nano-
String nCounter Elements™ protocol per the manufac-
turer’s instructions. All procedures regarding sample
preparation, hybridization, detection and scanning were
performed as recommended by NanoString Technologies
(NanoString, Seattle, WA). The custom probes (A and B)
were designed by IDT (IDT Technologies, Coralville, USA)
and contained 35–50 bp each, as previously described by
Lira and co-authors [13]. Probes were diluted to a final con-
centration of 0.6 nM (probe A) and 3.0 nM (probe B) to
create the 30X working probe pools. The total amount of
up to 100 ng RNA was used. RNA was hybridized with
probe pools, hybridization buffer and TagSet reagents in a
total volume of 30 μl and incubated at 67 °C for 20 h. Sam-
ples were then loaded to the automated nCounter Sample
Prep Station (NanoString Technologies, Seattle, WA),
which performed the purification steps and cartridge prep-
aration. Finally, the cartridges containing immobilized and
aligned reporter complexes were transferred to a nCounter
Digital Analyzer (NanoString Technologies), and expression
data were subsequently generated using the high-resolution
setting, which takes 600 images per sample.
Data analysis
The reporter counts were collected using NanoString’s
nSolver analysis software v2.5 and normalized as previously
described by Lira and co-authors [13]. Briefly, raw probe
counts were normalized by positive reaction controls to a
panel of three housekeeping genes (GUSB1, OAZ1 and
POLR2A). Additionally, a detection 3’/5’ score was defined
by the ratio between geometric mean of 3’-probes and aver-
age of 5’-probes, with a 2.0 threshold for positivity, as re-
ported by Lira and co-workers [13]. The statistical-
mathematical R software v.3.2.3 (https://www.r-project.org)
was used for this analysis and graphical construction.
Results
All 43 cases analyzed were previously evaluated by im-
munohistochemistry (Fig. 1a), which showed the pres-
ence of ALK positivity in 13/43 (30.2%) of cases. In a
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subset of cases (n = 24), we also performed FISH assays
(Fig. 1b). In these 24 cases, we found 100% concordance be-
tween the FISH and immunohistochemistry methodologies.
Concerning the NanoString assay, we first performed a
pilot analysis to determine whether a distinct initial
RNA quantity would yield equivalent results. Using the
H2228 (ALK-positive) cell line, we compared the use of
500 ng of RNA as reported by Lira and co-authors [13]
and 100 ng of RNA as recently suggested by NanoString.
We reported Pearson correlations of 0.99 for 5’-probes
and 0.93 for 3’-probes, with counts of EML-ALK V3a of
54.68 (100 ng) and 49.40 (500 ng), respectively (Fig. 2).
We further analyzed 43 cases, and of those, three were
excluded due to signal detection flags by NanoString
nSolver software. These three cases were from biopsies
and two of them yielded a total RNA quantity below
100 ng (Additional file 1: Table S1). The 3’/5’ score and
heatmap of normalized expression values of validated
cases (n = 40) are shown in Fig. 3a and b, respectively.
The concordance between the NanoString, immunohis-
tochemistry and FISH methodologies was 100%.
Among the 13 ALK-positive cases, the following vari-
ants were identified: six (46.15%) exhibited EML-ALK 1,
two (15.38%) exhibited EML-ALK 2, two (15.38%) exhib-
ited EML ALK-V3a, and three (23.07%) exhibited no
variant. However, in these cases, the increase in counts
in 3’-probes was evident, with average 3’/5’ scores of ap-
proximately 20 and normalized expression values of ap-
proximately 100 (case 1 to 13) (Fig. 3a and b). The
variant EML-ALK-V3a presented lower expression than
the others (case_3 and case_13), accounting for 57.61
and 82.67 of normalized NanoString counts, respect-
ively. These normalized values were similar to those ob-
served for the H2228 cell line, which also exhibited this
variant (Fig. 3b). No differences in KIF5B-ALK variants
were observed in the cases analyzed. TFG-ALK pre-
sented normalized values of approximately 40 in two
cases (Fig. 3b). However, this was not considered
relevant since the same patients presented higher
counts of EML-ALK 1. Moreover, similar normalized
values of TFG-ALK were also observed in ALK-nega-
tive patients (Fig. 3b).
Discussion
Aberrant ALK fusions were recently identified in a sub-
set of lung cancer patients, resulting in the constitutive
activation of MEK/ERK and PI3K pathways, with conse-
quent up-regulation of cell survival and proliferation
mechanisms [9, 21]. Importantly, its detection had a
paramount clinical impact, as it was a predictive bio-
marker of the therapeutic response [9, 21]. Recently, Lira
and co-authors [13] design a panel to detect ALK fusion
rearrangements by the NanoString assay. The authors
analyzed 34 ALK-positive and 33 ALK-negative FFPE
non-small cell lung cancer samples, obtaining 93% con-
cordance with FISH and 98% concordance with immu-
nohistochemistry [13]. For these analyses, the authors
used 500 ng of input RNA, which is an important value.
In the diagnostic procedures for lung cancer pathology,
the availability of sufficient quantities of biopsy tissue ul-
timately limit the application of these methodologies.
In the present study, we sought to implement the
NanoString panel of ALK fusion detection for lung can-
cer patients and to optimize its applicability in biopsies
using up to 100 ng of RNA. These small amounts are in
line with the recent protocols of NanoString for Ele-
ments. We analyzed the biopsy specimens of 43 patients
diagnosed with lung cancer, mainly non-small cell lung
cancer. Following RNA isolation, we observed the het-
erogeneity of RNA quality and quantity, representing the
reality of a routine setting. Despite the low quantities of
RNA used and their variable quality, only three cases
were flagged (3 ALK-negative), representing just ~7%
failure. The improvement of the panel, including the de-
tection of the clearly positive samples (according to 5’/3’
unbalanced probes) but detecting no variant, can also be
Fig. 1 ALK positivity represented by IHC (a) and the interphase nucleus with the presence of ALK rearrangement by FISH (score >15%) (b)
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of potential use. Our NanoString results were further
compared with FISH and immunohistochemistry ana-
lysis and showed a full concordance of methodologies.
Of the 40 cases with reliable results, 13 exhibited ALK
gene fusions. EML-ALK 1 was the most common, being
present in approximately half of them. These results are
in agreement with previous studies [4, 5].
It has been reported that the different variants can
exhibit distinct sensitivity to Crizotinib [22, 23]. Among
the methodologies currently available for ALK fusion de-
tection, only NanoString and next-generation sequen-
cing (NGS) can perform such differentiation (Table 1).
Recently, Rogers and co-authors compared the technics
of FISH, NanoString, Agena LungFusion panel and
ThermoFisher NGS [24]. The authors found a great con-
cordance between all techniques, and reported that
NanoString requires more RNA input, yet, is less prone
to false-positives [24]. Moreover, Ali and co-authors [25]
suggested that NGS could be especially useful for detect-
ing ALK rearrangements, including those with other
partners. One of the major advantages of NGS is the
potential for multiplex testing, but it has some disadvan-
tages, such as the higher cost, and it requires more effort
for analysis [26] (Table 1).
Furthermore, in Table 1, we address all current ALK re-
arrangement methodologies and explore their advantages
and disadvantages. As shown in Table 1, NanoString
represents an interesting option considering its hands-on
time, quantitative precision, robustness in samples with
extremely poor quality (since it is unbiased toward ampli-
fication and sequence errors) and ease of analysis. This
technique allows for the detection of a high number of
molecules similarly to microarrays, yet with a sensitivity
for qPCR [14]. Moreover, NanoString is very flexible for
the construction of custom panels, and it yields highly
confident, accurate and reproductive results in low quality
Fig. 2 NanoString correlation between the initial input of 100 or 500 ng in the H2228 cell line
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and quantity RNA from FFPE tissues [14]. However, it is
important to consider that this new technology has some
limitations, i) the high cost for hardware and software,
mainly for the process of acquisition and maintenance of
the devices, which has been limited in Latin America
(Table 1); and ii) considering the fusion assay, the detec-
tion is mainly detected by a previously defined 3’/5’ score,
which is not totally defined and it is not possible to detect
new fusion partners. In this regard, further studies are
necessary to expand the panel intending to include new
partners and to develop a defined analysis pipeline for
fusion detection, with specific thresholds for fusion probes
to avoid bias of interpretation.
Finally, in the future, with the novel standardizations
and improvements in chemistry to improve the sensitivity
at low input when compared with other technics [24]
Table 1 Comparison of FISH, IHC, qRT-PCR, NGS and NanoString regarding costs, procedural difficulty and resolution
FISH IHC qRT-PCR NGS NanoString
Costs Overal reagents costs */** *** **/*** * **/***
Hardware & software costs ** *** ** * *
Procedural difficulty RNA input required NA NA * *** **
Poor quality
samples
*/** **/*** * */** **/***
Hands on time */** */** ** */** ***
Run time and results analysis ** ** ** * **/***
Interpretation of results */** */** ** *** **
Throughput * */** ** *** **/***
Resolution Accuracy at low concentrations NA NA ** */** ***
Quantitative precision */** */** ** *** ***
Variants detection * * ** *** **/***
*-worse option; **-moderate option; *** - best option: NA Not applicable
Fig. 3 Barplot representing the ALK 3’/5’ score of each sample with the indication of the threshold line of positivity (a); Heatmap showing the
expression of 5’-ALK probes (exon 1 to exon 18) and 5’-ALK probes (exon 22 to 3’-UTR) and ALK variants (EML-ALK, KIF5B-ALK and TGF-ALK) (b)
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(Table 1), NanoString methodology can be used to address
special issues, such as the detection of ALK rearrange-
ments in CTCs [27].
Conclusions
In this study, we report the utility of NanoString technology
in the assessment of ALK fusions in FFPE specimens from
routine lung biopsies.
Additional file
Additional file 1: Table S1. Association of ALK fusion and the main clinico-
pathological and molecular features. Summary of the major clinico-pathological
characteristics of patients and RNA quality information and ALK, EGFR and KRAS
status. (XLSX 14 kb)
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